• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Edema

Edema - 306 Studies Found

Completed : Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
: Hereditary Angioedema
: 2011-05-19
: Drug: rhC1INH Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The
Terminated : Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema
: ACE Inhibitor-associated Angioedema
: 2011-12-14
:
  • Drug: icatibant Subcutaneous a

Completed : Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks
: Hereditary Angioedema
: 2012-06-29
: Biological: CINRYZE with rHuPH20 Other Names:
  • C1 esterase inhibitor (hu

Completed : A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
: Hereditary Angioedema Types I and II
: 2013-07-29
:
  • Biological: Low-volume C1-esterase inhibitor

Completed : Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
: Hereditary Angioedema
: 2007-04-04
: Drug: ecallantide solution for SC injection, one 30 mg dose per HAE attack
Completed : A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
: Hereditary Angioedema
: 2009-06-02
:
  • Drug: Icatibant Single subcuta

Completed : Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)
: Hereditary Angioedema
: 2007-07-12
:
  • Drug: Icatibant Icatibant: a s

Withdrawn : Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema
: Hereditary Angioedema
: 2010-12-02
: Biological: ecallantide 10 - 30mg subcutaneous injection.
Completed : CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
: Hereditary Angioedema
: 2010-03-24
: Biological: CINRYZE Other Name: C1 inhibitor [human]
Completed : Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema (HAE) Subjects
: Hereditary Angioedema
: 2014-03-17
:
  • Drug: DX-2930 DX-2930 is a rec

<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.